AND Guidelines Bundle

Gestational Diabetes Mellitus

AND GUIDELINES App Bundle brought to you fcourtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: http://eguideline.guidelinecentral.com/i/954051

Contents of this Issue

Navigation

Page 9 of 9

Disclaimer This Guideline attempts to define principles of practice that should produce high-quality patient care. It is applicable to specialists, primary care, and providers at all levels. This Guideline should not be considered exclusive of other methods of care reasonably directed at obtaining the same results. The ultimate judgment concerning the propriety of any course of conduct must be made by the clinician after consideration of each individual patient situation. Neither IGC, the medical associations, nor the authors endorse any product or service associated with the distributor of this clinical reference tool. Abbreviations A1C, glycosylated hemoglobin; ADI, acceptable daily intake; BMI, body mass index; GDM, gestational diabetes mellitus; CHO, carbohydrate; DRI, Dietary Reference Intakes; FDA, US Food and Drug Administration; MNT, medical nutrition therapy; GI, glycemic index; GCT, glucose challenge test; GRAS, generally recognized as safe; LGA, large-for-gestational-age/ macrosomia; GWG, gestational weight gain; RDN, registered dietitian nutritionist; OGTT, oral glucose tolerance test; PPBG, post-prandial blood glucose; SMBG, self-monitoring blood glucose Source Academy of Nutrition and Dietetics. Gestational Diabetes (2016) Evidence-Based Nutrition Practice Guideline, Chicago, IL. To view the entire Gestational Diabetes 2016 Guideline, including introduction, scope, harms/benefits and supporting evidence, visit www.andeal.org/gdm 106 Commerce Street, Suite 105 Lake Mary, FL 32746 TEL: 407.878.7606 • FAX: 407.878.7611 Order additional copies at GuidelineCentral.com Copyright © 2018 All rights reserved ANDGDM1813 Criteria for Recommendation Ratings Statement Definition Strong • Benefits clearly exceed the harms (or harms clearly exceed the benefits for a negative recommendation) • The quality of the supporting evidence is excellent/good (grade I or II) Fair • Benefits exceed the harms (or harms clearly exceed the benefits for a negative recommendation) • Quality of evidence is not as strong (grade II or III) Weak • Quality of evidence that exists is suspect • Or that well-done studies (grade I, II or III) show little clear advantage to one approach versus another Consensus • Expert opinion (grade IV) supports the guideline recommendation Insufficient Evidence • Both a lack of pertinent evidence (grade V) and/or an unclear balance between benefits and harms

Articles in this issue

Links on this page

Archives of this issue

view archives of AND Guidelines Bundle - Gestational Diabetes Mellitus